Info@ThinkPinkRocks.com

Bayer’s Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

View article:
Bayer’s Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Share

Leave a Reply